189 related articles for article (PubMed ID: 38674098)
1. Prognostic Value of "Basal-like" Morphology, Tumor-Infiltrating Lymphocytes and Multi-MAGE-A Expression in Triple-Negative Breast Cancer.
Čeprnja T; Tomić S; Perić Balja M; Marušić Z; Blažićević V; Spagnoli GC; Juretić A; Čapkun V; Vuger AT; Pogorelić Z; Mrklić I
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674098
[TBL] [Abstract][Full Text] [Related]
2. Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma.
Hoda RS; Brogi E; Dos Anjos CH; Grabenstetter A; Ventura K; Patil S; Selenica P; Weigelt B; Reis-Filho JS; Traina T; Robson M; Norton L; Wen HY
Mod Pathol; 2020 Nov; 33(11):2221-2232. PubMed ID: 32612248
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer.
Lee J; Kim DM; Lee A
Cancer Res Treat; 2019 Apr; 51(2):649-663. PubMed ID: 30064200
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
5. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
6. Co-expression of cancer testis antigens and topoisomerase 2-alpha in triple negative breast carcinomas.
Mrklić I; Spagnoli GC; Juretić A; Pogorelić Z; Tomić S
Acta Histochem; 2014 Jun; 116(5):740-6. PubMed ID: 24560456
[TBL] [Abstract][Full Text] [Related]
7. Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study.
Sarradin V; Lusque A; Filleron T; Dalenc F; Franchet C
Breast Cancer Res; 2021 May; 23(1):61. PubMed ID: 34039396
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 (SP142) Expression in Primary and Recurrent/Metastatic Triple-Negative Breast Cancers and Its Clinicopathological Significance.
Han EK; Woo JW; Suh KJ; Kim SH; Kim JH; Park SY
Cancer Res Treat; 2024 Apr; 56(2):557-566. PubMed ID: 38097920
[TBL] [Abstract][Full Text] [Related]
9. Assessing the relationship between tumor-infiltrating lymphocytes and PD-L1 expression in triple negative breast cancer: Identifying optimal TILs cut-off value for pathologic reporting.
Suwannaphoom K; Soontornsit S; Wiwatwarayos K; Seneetuntigul P; Julimasart P
Ann Diagn Pathol; 2024 Jun; 70():152294. PubMed ID: 38513466
[TBL] [Abstract][Full Text] [Related]
10. Molecular Characteristics of Lymphocyte-predominant Triple-negative Breast Cancer.
Sasaki R; Horimoto Y; Yanai Y; Kurisaki-Arakawa A; Arakawa A; Nakai K; Saito M; Saito T
Anticancer Res; 2021 Apr; 41(4):2133-2140. PubMed ID: 33813424
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
Wang X; Liu Y
Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
[TBL] [Abstract][Full Text] [Related]
12. The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer.
Mori H; Kubo M; Yamaguchi R; Nishimura R; Osako T; Arima N; Okumura Y; Okido M; Yamada M; Kai M; Kishimoto J; Oda Y; Nakamura M
Oncotarget; 2017 Feb; 8(9):15584-15592. PubMed ID: 28107186
[TBL] [Abstract][Full Text] [Related]
13. Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer.
Zhu X; Zhang Q; Wang D; Liu C; Han B; Yang JM
Cancer Biol Ther; 2019; 20(8):1105-1112. PubMed ID: 30929569
[No Abstract] [Full Text] [Related]
14. Genomic alterations affecting tumor-infiltrating lymphocytes and PD-L1 expression patterns in triple-negative breast cancer.
Wang H; Ding XH; Liu CL; Xiao Y; Shui RH; Li YP; Chen C; Yang WT; Liu S; Chen CS; Shao ZM; Jiang YZ
J Natl Cancer Inst; 2023 Dec; 115(12):1586-1596. PubMed ID: 37549066
[TBL] [Abstract][Full Text] [Related]
15. Histological subtype is associated with PD-L1 expression and CD8+ T-cell infiltrates in triple-negative breast carcinoma.
Salisbury T; Abozina A; Zhang C; Mao E; Banyi N; Leo J; Ionescu D; Zhou C; Wang G
Ann Diagn Pathol; 2022 Apr; 57():151901. PubMed ID: 35091156
[TBL] [Abstract][Full Text] [Related]
16. A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma.
Tavares MC; Sampaio CD; Lima GE; Andrade VP; Gonçalves DG; Macedo MP; Cordeiro de Lima VC
BMC Cancer; 2021 Aug; 21(1):901. PubMed ID: 34362334
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
Li M; Li A; Zhou S; Xu Y; Xiao Y; Bi R; Yang W
BMC Cancer; 2018 Jan; 18(1):4. PubMed ID: 29291717
[TBL] [Abstract][Full Text] [Related]
18. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
[TBL] [Abstract][Full Text] [Related]
19. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
Zhang L; Wang XI; Ding J; Sun Q; Zhang S
Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
[TBL] [Abstract][Full Text] [Related]
20. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
